Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 12 of 12 for “"Treatment of pancreatic cancer."”.
-
Development of novel antibody-targeted nanoparticle strategies for treatment of pancreatic cancer
Despite major advancements in the treatment of many cancers, pancreatic cancer has one of the poorest survival rates of all, with a ten-year survival of less than 1%. One experimental clinical approach to treat pancreatic cancer had involved targeting an apoptosis pathway, the TNF-related …
-
The development of next-generation antibody based therapeutics for the treatment of pancreatic cancer
Pancreatic cancer is an extremely challenging disease in dire need of improved detection methods and therapeutics. Currently, less than 20% of patients are eligible for surgery at the time of diagnosis, the only potentially curative treatment regimen available. Many of the remaining 80%+ of …
-
The development and characterisation of MicroRNA and gemcitabine nanotherapies for the treatment of pancreatic cancer
Pancreatic cancer has been considered as the most lethal cancer type among adults for many decades. Especially with the failure to improve survival rates for the last 40 years, despite all the progress in targeting therapies. With the lack of therapeutic options, attention has been directed towards …
-
The Biological and Immunological Effects of Irreversible Electroporation and Combination Therapy Options for the Improving the Treatment of Pancreatic Cancer
While cancer treatments have advanced for multiple cancers, pancreatic cancer remains a lethal cancer with few therapy options available. This is due to the inaccessibility of the tumor by surgical and thermal ablative means, high potential for chemoresistance and metastasis, and strongly …
-
the impact of Ape/Ref1 on hypoxia regulated genes; potential applications for cancer
Pancreatic cancer is especially a deadly form of cancer with a survival rate less than 2%. Pancreatic cancers respond poorly to existing chemotherapeutic agents and radiation, and progress for the treatment of pancreatic cancer remains elusive. To address this unmet medical need, a better …
-
Analysis of soluble high-affinity PD1 variants
… significant clinical impact in several major cancer types such as melanoma or Hodgkin’s lymphoma, immunotherapies have not had much success in the treatment of pancreatic cancer. This cancer is characterised by a pro-inflammatory and immunosuppressive stroma which causes aggressive cancer …
-
The development and evaluation of multifunctional silver iron-oxide hybrid nanoparticles towards enhanced pancreatic cancer therapy
Pancreatic cancer is the most aggressive of all common cancers and possesses high resistance to treatment, leading to poor survival outcomes. Lack of drug efficacy is a major issue faced by patients. The nanomedicine community are striving to develop innovative technologies, such as nanoparticle …
-
Advancing the Preclinical Development of Secondary Metabolites from Cacospongia mycofijiensis for the Treatment of Cancer
<p>The marine sponge <em>Cacospongia mycofijiensis</em> from the Indo-Pacific has proven to be a source of structurally diverse secondary metabolites that are biologically active against a variety of distinct targets. Current interest in the secondary metabolites of <em>C. mycofijiensis …
-
Clinical review and experimental evaluation of tumour M2-pyruvate kinase in pancreatic cancer
The treatment of pancreatic cancer is challenging. Patients are often beyond curative surgical therapy and palliative treatment with chemotherapy provides limited benefit. New markers of cancer activity and therapeutic targets are required. This thesis has firstly reviewed the available literature …
-
Repurposing itraconazole as a novel and promising therapeutic strategy for pancreatic cancer
Pancreatic cancer has the highest mortality rate among all main cancer types and is the 3rd leading cause of cancer death in Australia. Standard chemotherapy for advanced pancreatic cancer only imparts a modest clinical benefit as the overall 5-year survival of all stages of the disease remains …
-
Anti-CD47 targeting therapy for the treatment of colon and pancreas cancers.
CD47 is a "don't eat me" signal over expressed on cancer cells inhibiting their engulfment by phagocytes. A novel monoclonal antibody, Hu5F9-G4, blocking CD47's interaction with its ligand SIRPα allowed for phagocytosis of colorectal and pancreas tumors by macrophages. In some models, treatment of …